Roche

October 4, 2017October 4, 2017

Europe Approves Tecentriq Therapy for Advanced or Metastatic NSCLC

Lung Cancer, News

Patients in the European Union who have advanced or metastatic non-small cell lung cancer (NSCLC) now can be treated with Roche’s Tecentriq (atezolizumab). According to the European Commission marketing authorization, ... Read more

June 30, 2017June 30, 2017

New Esbriet Tablets for IPF Treatment Now Available in Europe

Idiopathic Pulmonary Fibrosis, News

The European Commission has approved a new formulation of Esbriet (pirfenidone) tablets for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). Esbriet, developed by Roche, is an oral antifibrotic medication approved ... Read more

May 25, 2017May 25, 2017

Esbriet Subgroup Analyses Suggest Benefits Also in Moderate and Severe IPF

Idiopathic Pulmonary Fibrosis, News

Patients with more severe idiopathic pulmonary fibrosis (IPF) also benefit from Esbriet (pirfenidone) treatment, as do IPF patients with moderate lung function impairment, according to two studies presented at the ... Read more

July 2, 2015November 6, 2015

Study Presented at EULAR Shows Roche’s Esbriet Meets Safety Targets in Systemic Sclerosis-related Interstitial Lung Disease

News, Scleroderma

Results from a recent open-label trial presented during the European League Against Rheumatism Annual European Congress of Rheumatology showed that ESBRIET met its safety endpoint in the treatment of interstitial lung ... Read more

June 11, 2015November 6, 2015

Breakthrough Therapy Status Granted to Roche’s SSc Treatment

News, Scleroderma

Roche was recently granted breakthrough therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for its combined treatment ACTEMRA/RoACTEMRA (tocilizumab) for systemic sclerosis (SSc). The status was awarded based on successful ... Read more

September 30, 2014November 6, 2015

FDA Includes Heart and Brain Problems to Asthma Drug Xolair’s Potential Risks

Asthma, News

The U.S. Food and Drug Administration (FDA) recently reviewed its drug safety recommendations, suggesting an increase in the risk of heart and blood problems as a result of the use of Xolair ... Read more